Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 3/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.51 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | GOT1 | P17174 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22803873 | 0.86 | EPHX2 (0.55) | EPHX2ESR1MTORSTING1BAZ1A | |
| SCHEMBL22803571 | 0.86 | EPHX2 (0.55) | EPHX2ESR1MTORSTING1BAZ1A | |
| SCHEMBL22803291 | 0.85 | EPHX2 (0.54) | EPHX2ESR1MTORSTING1BAZ1A | |
| SCHEMBL22803568 | 0.84 | EPHX2 (0.52) | EPHX2ESR1MTORSTING1BAZ1A | |
| SCHEMBL22778031 | 0.83 | STING1 (0.58) | EPHX2ESR1MTORSTING1BAZ1A | |
| SCHEMBL29714421 | 0.83 | STING1 (0.58) | EPHX2ESR1MTORSTING1BAZ1A | |
| SCHEMBL22803587 | 0.83 | EPHX2 (0.51) | EPHX2ESR1MTORSTING1BAZ1A | |
| SCHEMBL22803879 | 0.83 | EPHX2 (0.51) | EPHX2ESR1MTORSTING1BAZ1A | |
| SCHEMBL22803722 | 0.82 | STING1 (0.52) | EPHX2ESR1MTORSTING1BAZ1A | |
| SCHEMBL22803884 | 0.82 | EPHX2 (0.50) | EPHX2ESR1MTORSTING1BAZ1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | EPHX2 2928/4885ESR1 3661/4885MTOR 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.